BHVN Company Profile and Key Details

BHVN has shown mixed momentum, gaining 7.09% over the past week and -20.5% over the past quarter, though year-to-date performance is up 12.31%. Short-term trend indicators are mixed aligned (SMA20 -3.79%, SMA50 -3.79%, SMA200 -17.64%). The stock’s 14-day RSI is 44.96 (neutral), while the ATR of 0.75 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -70.83% below its high and over 49.06% above its low. Average 10-day trading volume of 2.47 million shares is below the 3-month average of 2.74 million, indicating normal recent market interest.

Biohaven Ltd. has 105.79 million shares outstanding. The public float is 88.38 million shares, elevated short interest at 11.64% of float. This equals 10.95 million shares. The short ratio is 4.29 days. Institutional investors hold 93.5% of the float. Insiders own 11.55%. CHILDS JOHN W holds 5.65 million shares, Bailey Gregory has 2.02 million shares and Doogan Declan has 870.65 thousand shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Biohaven Ltd. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around -$0.45. This means the shares are trading below this model’s fair value.

Biohaven Ltd. (NYSE:BHVN) closed at $8.39 USD, losing -$0.35 (-4.00%) from the previous close of $8.74. The stock is currently mid-range between its 52-week high and low $7.48 and $31.18. With a market capitalization of about $888.21 million, Biohaven Ltd. is classified as a small-cap and shows higher-than-market volatility (beta ~3.53). Key stats such as the average daily volume over the past year has been around 2.77 million shares, in line with its 52-week average. Headquartered in New Haven, CT, Biohaven Ltd. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Vladimir Coric, the company employs approximately 256 people and listed since September 23, 2022. Biohaven Ltd. is a clinical-stage biopharmaceutical company.

Biohaven Ltd. generated EPS of -$7.60 over the past year. Five-year average earnings growth is -49.78%. Wall Street analysts project EPS growth of 37.31% annually over the next five years. The latest quarter delivered EPS of -$1.64. The next quarter is forecast at -$1.19. Next year's EPS is expected at -$1.88. Analyst sentiment is bullish. Analyst rating data shows there are 10 Strong Buy ratings, 10 Buy ratings, 6 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $75.00 to $9.00. The high target offers 793.92% upside. The low target suggests 7.27% downside. The mean target is $29.92. This offers 256.62% upside. Biohaven Ltd. earnings surprise history is a consistent trend of beating forecasts. The quarter that ended November 10, 2025, missed forecasts by -14.18%. The prior quarter beat by 0.0%. Over the last six quarters, Apple has recorded several small beats. These include 111.63% in August 08, 2024.

Biohaven Ltd. (NYSE:BHVN) shares are up 12.31% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Biohaven Ltd. trading at a premium to the broader market with a P/E of -1.39. Analyst sentiment is bullish, with the majority of ratings in Buy territory and a mean price target of $53.37, suggesting 536.11% upside. Our AI forecast model points to short-term weakness (-17.16% over two weeks), a medium-term fall (-25.51% over three months), and a longer-term loss (-60.67% over one year), with expected trading ranges indicating moderate volatility.

Our AI price prediction model suggests that Biohaven Ltd. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected decline of -17.16%, with price expected at $6.95 by April 07, 2026, within a range of $6.50 to $7.38 3-Month Outlook: Projected fall of -25.51%, reaching $6.25 by June 22, 2026, with a range of $5.65 to $6.91. 1-Year Outlook: Projected loss of -60.67%, with price at $3.30 by March 24, 2027, within a range of $0.00 to $0.00.

Biohaven Ltd. trades at a P/E ratio of -1.39, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 19.68 reflecting a rich premium to book value. The P/FCF stands at -1.48, also above market averages. Compared to sector medians, Biohaven Ltd. P/S is trading at a discount to the sector, and the P/B is far higher than peers, underscoring the brand and earnings power premium investors assign to the stock.